Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?
- 1 April 1998
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 346 (1) , 1-13
- https://doi.org/10.1016/s0014-2999(98)00093-4
Abstract
No abstract availableKeywords
This publication has 117 references indexed in Scilit:
- Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brainNeurobiology of Aging, 1997
- Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseLife Sciences, 1996
- Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in micePublished by Elsevier ,1995
- Metrifonate effects on acetylcholine and biogenic amines in rat cortexNeurochemical Research, 1995
- Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: Implications for cholinergic-based therapiesLife Sciences, 1995
- Memory disorders: Novel treatments, clinical perspectiveLife Sciences, 1994
- Cholinergic and serotonergic stimulation of phosphoinositide hydrolysis is decreased in Alzheimer's diseaseLife Sciences, 1994
- Coupling of muscarinic receptors to GTP proteins in postmortem human brain — alterations in Alzheimer's diseaseNeuroscience Letters, 1993
- Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's diseaseNeurobiology of Aging, 1992
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986